AI

SLS Stock Today Surges 281%

Times News policy-spillover note (2026-11-17): SELLAS Life Sciences (NASDAQ: SLS) shares surged more than 281%, climbing above $28 on trading volume exceeding 200 million shares after the company announced… Primary source: original at Coinpedia (coinpedia.org).

· Coinpedia

SLS Stock Today Surges 281%

SELLAS Life Sciences (NASDAQ: SLS) shares surged more than 281%, climbing above $28 on trading volume exceeding 200 million shares after the company announced positive results from its pivotal Phase 3 REGAL trial. The trial showed a statistically significant and clinically meaningful improvement in overall survival among patients with acute myeloid leukemia (AML) treated with its cancer vaccine, Galinpepimut-S (GPS). The results could trigger significant short covering, with 57.1 million SLS shares sold short as of October 30, representing 28% of outstanding shares. However, analysts warn that a potential stock offering to fund regulatory filings and commercialization could limit further gains and reduce short-squeeze momentum.

Was this writing helpful?

Trust with CoinPedia:

CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:

All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:

Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.